Novo Nordisk, the developer of the popular diabetic medications sold under the brand names Ozempic and Wegovy, has been sued by a woman who claims that the labeling of the drug does not often warn about the possible adverse effects. The action was launched against Novo Nordisk.

Juanita Gantt said on CBS Mornings that one of these adverse affects had an effect on her colon, which she claims required removal as a consequence of the medicine she was taking.

Regarding the allegations, Novo Nordisk has provided a response, stating that the lawsuit is “without merit.”

She was first administered Wegovy, and subsequently Ozempic, according to Gantt, because her physician believed that she was experiencing an increased likelihood of getting diabetes. She reported to CBS that the 62-year-old individual weighed 242 pounds.

In the beginning, she said, “I was feeling very well. On days when I didn’t have to worry about my hunger, I found it to be really enjoyable. The urges did not come to me. Simply put, I had the impression that I was doing something constructive for myself.

On the other hand, Gantt claims that her husband discovered her comatose on the floor in October of 2023.

She disclosed to CBS that portions of her big intestine had perished and needed to be removed; she fell into cardiac arrest while she was recuperating from surgery.

Eileostomy bags are now a part of her daily life. According to the Cleveland Clinic, it is the consequence of a surgical procedure that alters the approach that your body takes to the elimination of waste.

According to the site, “Poop is expelled from your body through the new hole and collects in an ostomy bag that adheres to your skin for collection.”

On the other hand, Gantt said to CBS that “I had no warning that this was even a possibility before.”

The GLP-1 receptor agonists semaglutide and liraglutide, which are the primary components of Ozempic, Wegovy, and other medications of a similar kind, have the potential to slow down the digestion of meals if they are used for a prolonged length of time.

In July of last year, the possible effects of the prescription on digestion made news when other people who took the pills reported that they acquired gastroparesis, also known as stomach paralysis, which is a condition that slows down the process of digesting to an unhealthy degree.

PEOPLE received a statement from a representative of Novo Nordisk, who said, “We are aware of the health challenges this patient has experienced and are sympathetic to her health journey.” At Novo Nordisk, we place a high premium on the safety of our patients, and we collaborate closely with the Food and Drug Administration of the United States to ensure that the safety profile of our medications is regularly monitored.

Novo Nordisk, on the other hand, is of the opinion that the accusations that are being made in this action are without foundation, and we plan to strongly defend ourselves against these claims. Since more than 19 years ago, GLP-1 medications have been used for the treatment of type 2 diabetes (T2D), and for about ten years, they have been utilized for the treatment of obesity. This includes many GLP-1 medications manufactured by Novo Nordisk, including as semaglutide and liraglutide, which have been available for purchase for more than thirteen years. An considerable amount of research has been conducted on semaglutide, which has been subjected to rigorous clinical development programs, substantial real-world evidence studies, and a combined total of over 9.5 million patient years of clinical experience.

“The FDA-approved product labeling for semaglutide and liraglutide medications includes a description of the known risks and benefits associated with these medications. Novo Nordisk is confident in the safety and effectiveness of all of our GLP-1 medications, provided that they are taken in accordance with the instructions provided by a qualified medical expert and that they are used in the manner that is recommended.

The firm reached out to PEOPLE in order to add the following statement: “As was noted previously, patient safety is our primary focus. This is the reason why we offer a fairly balanced assessment of known dangers when we market our FDA-approved prescription drugs (for example, when we advertise on television or online). Additionally, there are Medication Guides available for consumers, as well as Prescribing Information in the case of medical professionals. Consumers are constantly advised to speak with their healthcare practitioner, and safety information is given the utmost importance throughout all of our advertisements that are shown on television.